Kamada completes last patient visit in Phase II bronchiectasis study

The trial, which was a double-blind, placebo-controlled study, was performed at the Rabin Medical Center, Campus Beilinson in Israel. A total of 21 patients were randomized 2:1 to inhaled alpha-1 antitrypsin (AAT) or placebo and received the drug daily for 12 weeks.

Preliminary results indicate that the product continues to demonstrate a good safety profile; final analysis of airway inflammation and secondary endpoints is expected to be available by mid-year, said Kamada.

David Tsur, Kamada’s CEO, said: “This is another milestone for Kamada in the development of inhaled AAT. Bronchiectasis affects approximately 600,000 people worldwide and we believe our novel approach, which could impact the underlying inflammatory processes, may considerably improve the quality of life of these patients. We look forward to receiving the final data from this study in the coming months.”